Question 1

Has Alejandro Rodarte Rascon received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $1,258 in general payments to Alejandro Rodarte Rascon across 53 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Alejandro Rodarte Rascon did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Alejandro Rodarte Rascon come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
SK Life Science, Inc.	8	$232
UCB, Inc.	11	$222
Novartis	3	$83
AstraZeneca	4	$80
Argenx US, Inc.	3	$79
Jazz Pharmaceuticals Inc.	2	$58
Takeda Pharmaceuticals U.S.A., Inc.	2	$57
AbbVie	2	$49
Acadia Pharmaceuticals Inc	2	$45
Catalyst Pharmaceuticals, Inc.	2	$42
Mallinckrodt Hospital Products Inc.	1	$37
Amgen	2	$36
Eisai Inc.	2	$35
Neurocrine Biosciences, Inc.	1	$31
Baxter Healthcare	1	$28
Immedica Pharma US, Inc.	1	$27
Acorda Therapeutics, Inc	1	$21
Merz Pharmaceuticals, LLC	1	$20
Tanabe Pharma America, Inc.	1	$20
Sanofi	1	$20
Genentech USA, Inc.	1	$20
Biogen	1	$18

Alejandro Rodarte Rascon

Payments from drug & device makers

Who reported the general payments

Most prescribed under Part D